MétaCan
Menu
← Back to cohort

Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC).

2016· article· en· W2532258671 on OpenAlexaff
Mark Doherty, Grzegorz Korpanty, Pascale Tomasini, Moein Alizadeh, Kevin Jao, Catherine Labbé, Céline Mascaux, Petra Martin, Suzanne Kamel‐Reid, Melania Pintilie, Geoffrey Liu, Penelope Ann Bradbury, Ronald Feld, Natasha B. Leighl, Caroline Chung, Frances A. Shepherd

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsUniversity of TorontoCentre Integre de Sante et de Services Sociaux de LavalUniversity Health NetworkPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineInternal medicineBrain metastasisOncologyNeurocognitiveLung cancerStage (stratigraphy)Systemic therapyPerformance statusCancerBreast cancerMetastasisCognition

Abstract

fetched live from OpenAlex

e20527 Background: Survival with EGFR/ALK+ve NSCLC can be prolonged with tyrosine kinase inhibitors (TKIs), but brain metastases (mets) are common. TKIs may control brain mets poorly, and radiation may have neurocognitive toxicity. Deteriorating performance status (PS) due to brain mets may affect the number of lines of treatment. We aimed to evaluate the impact of brain mets on lines of systemic therapy and overall survival (OS). Methods: This retrospective analysis included patients with EGFR/ALK+ve NSCLC treated at Princess Margaret Cancer Centre from 1998-2015. 2 groups were analyzed: those with brain mets at diagnosis of stage IV disease or on 1st line therapy, and those without brain mets. OS was calculated from date of metastatic disease using Kaplan-Meier method, and differences between groups were tested with the log-rank test. Results: 291 patients were included: 141 with and 150 without brain mets. Summary results are shown in the Table. 106/141 had brain mets at diagnosis of stage IV NSCLC. There were more patients with relapsed early stage NSCLC in the no brain mets group (29% vs 19%), and more smokers in the brain mets group (18% vs 7%). 1st treatment for brain mets included WBRT (84), SRS (32) and TKI alone (24). 1st line systemic therapy was TKI in 83% of brain mets group and 61% of no brain mets group. Median OS was longer in the no brain mets group: 4 vs 2.1 years, HR 1.55, p=0.013. There was no observed difference in number of treatment lines: median 1 in both groups, p=0.53. Conclusions: Patients with brain mets from EGFR/ALK+ve NSCLC have inferior OS, despite TKIs and similar exposure to systemic therapy. Further focus on this group is necessary to improve outcomes. No Brain mets N=150 Brain mets N=141 P Age Median (Range) 61.9(27.6- 82.9) 59.8(29.2- 86.3) 0.35 Female 98(65%) 96(68%) 0.71 Smoking History No 139(93%) 115(82%) 0.005 Yes 11(7%) 26(18%) Ethnicity Asian 72(48%) 63(45%) 0.85 Caucasian 55(37%) 56(40%) Other 23(15%) 22(15%) ECOG PS 0-1 141(94%) 133(94%) 0.72 2-3 9(6%) 8(6%) Stage IV at First Dx 106(71%) 114(81%) 0.056 Mutation ALK 21(14%) 14(10%) 0.37 EGFR 129(86%) 127(90%) Lines of treatment Median(range) 1(0-9) 1(0-4) 0.53 Median Survival Years 4.0 2.1 0.011 HR 1.55 (95%CI 1.1-2.2)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.475
Teacher spread0.426 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicLung Cancer Treatments and Mutations→French-language works237,207→